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Havel, Peter J., Bonnie L. Busch, Donald L. Curry, 
Patricia R. Johnson, Mary F. Dallman, and Judith S. 
Stern. Predominately glucocorticoid agonist actions of RU- 
486 in young specific-pathogen-free Zucker rats. Am. J. 
Physiol. 271 (Regulatory Integrative Comp. Physiol. 40): 
R710-R717, 1996.-Previous studies have demonstrated an- 
tiglucocorticoid actions for the progesterone receptor antago- 
nist RU-486. In one study, daily administration of this drug 
for 2 wk decreased food intake (FI) and body weight gain 
(ABW) in obese, but not lean, conventionally housed 5wk-old 
female Zucker rats. We recently found that 2-wk administra- 
tion of RU-486 attenuated ABW in lean but not obese 
12-wk-old male Zucker rats without affecting FI. To examine 
the actions of RU-486 and its effects on FI and ABW in young 
(5 wk old) specific-pathogen-free (SPF) male and female 
Zucker rats, RU-486 was administered at 30 mg l kg- * l day l 
subcutaneously for 14 days. RU-486 did not affect FI in obese 
or lean male or female rats. RU-486 increased adrenal weight 
(P < 0.05) overall and in lean female rats and modestly 
decreased inguinal fat weight overall and in obese female rats 
(P < O.Ol), suggesting some antiglucocorticoid activity in 
these animals. However, RU-486 also decreased thymus 
weight by 18-31s (P < O.OOOl>, increased plasma glucose by 
lo-16 mg/dl (P < 0.002), and increased plasma insulin by 
47% in obese male rats (P < 0.028>, demonstrating glucocorti- 
coid agonist actions for the drug. Plasma corticosterone (B) 
and adrenocorticotropic hormone (ACTH) were elevated in 
vehicle-treated obese female and male rats by 150-3600/G (P < 
0.0025) and 32-38s~ (P < 0.05), respectively, compared with 
lean rats. RU-486 treatment lowered the elevated plasma B 
and ACTH levels in obese female and male rats (both P < 0.02 
vs. vehicle), a glucocorticoid agonist effect. We conclude that 
in young SPF Zucker rats 1) RU-486 administration does not 
alter FI or ABW, 2) RU-486 has predominately glucocorticoid 
agonist actions in several tissues, 3) obese animals have 
increased hypothalamic-pituitary-adrenal (HPA) axis activ- 
ity (plasma B and ACTH), and 4) RU-486 administration 
suppresses the HPA axis in obese rats. 
mifepristone; thymus; adrenal; glucose; insulin; glucagon; 
pancreatic polypeptide; corticosterone; adrenocorticotropic 
hormone 
THE FATTY (falfa) Zucker rat has been used for over 35 
years for investigation of the physiological and biochemi- 
cal features of obesity. Recent evidence indicates that 
the primary genetic defect responsible for obesity in 
fatty Zucker rats is a mutation in the gene coding for a 
receptor for the adipose tissue protein leptin (10). 
Leptin is likely to act as a humoral signal from body fat 
stores to the central nervous system, where it acts to 
limit food intake and increase energy expenditure (38). 
The hypothalamic-pituitary-adrenal (HPA) axis is also 
involved in the regulation of body weight and adiposity 
(6). For example, obese Zucker rats have elevated basal 
and stimulated plasma corticosterone levels (16, 34), 
and surgical adrenalectomy attenuates food intake, 
body weight, and adiposity and increases energy expen- 
diture in several animal models of obesity including 
obese Zucker rats (13), oblob mice (45), and obesity 
resulting from ventromedial hypothalamus lesions (43). 
Reduced feedback inhibition of central corticotropin- 
releasing hormone (CRH) by circulating glucocorticoids 
is likely to contribute to the antiobesity effects of 
adrenalectomy, because central administration of CRH 
reduces body weight (2, 39) and increases energy 
expenditure (40) in obese Zucker rats and increases 
sympathetic outflow in normal rats (7). 
A number of studies have demonstrated antiglucocor- 
ticoid actions for the progesterone receptor antagonist 
RU-486 both in vivo and in vitro (3, 9, 14, 28). In one 
study, daily administration of RU-486 for 2 wk de- 
creased food intake and body weight gain in obese but 
not lean 5wk-old female conventionally housed Zucker 
rats (27). Plasma corticosterone was increased in both 
obese and lean rats treated with RU-486, suggesting 
that the actions of the drug in the obese animals were 
due to glucocorticoid antagonist effects on the HPA 
axis, presumably by blocking negative feedback inhibi- 
tion of CRH and adrenocorticotropic hormone (ACTH) 
by endogenous corticosterone. 
In contrast, we have found that daily administration 
of RU-486 did not affect food intake but prevented body 
weight gain in lean, but not obese, 12-wk-old male 
Zucker rats (IS), suggesting that the actions of RU-486 
in Zucker rats are more complex than a pure glucocorti- 
coid receptor antagonist and may be dependent on 
variables related to the subject animals. Therefore, to 
examine the effects of RU-486 on food intake and body 
weight in younger animals, we administered RU-486 or 
vehicle daily for 2 wk to 5-wk-old male and female obese 
and lean specific-pathogen-free (SPF) Zucker rats (41). 
SPF animals were studied because these animals are 
known to be free of a large number of endemic viral and 
other pathogens that can induce chronic illness and 
stress in conventionally housed rodents (23, 32). Adre- 
nal weight, thymus weight, plasma insulin, and glucose 
were measured as physiological indexes of glucocorti- 
coid or antiglucocorticoid activity. Plasma corticoste- 
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Table 1. Pathogens screened for in SPF Zucker rat (BAT), and ovaries from female rats were removed and 
breeding colony weighed. 
Pathogen 
Mycoplasma pulmonis 
Cilia-associated respiratory 
bacillus 
Sendai virus 
Kilham rat virus 
H-l rat parvovirus 
Rat corona virus 
Pneumonia virus of mice 
Mouse adenovirus 
Reovirus-3 
Lymphocytic choriomeningitis 
virus 
Theiler murine encephalitis 
virus 
Syphacia muris (rodent pin- 
worm) 
Radfordia ensifera (rat fur mite) 
Pathogenicity 
Respiratory pathogen 
Respiratory pathogen 
Immunosuppressive virus 
CNS and gonadal pathogen 
Similar to Kilham rat virus 
Salivary gland pathogen 
Subclinical disease in rats 
Subclinical disease in rats 
Immunosuppressive virus 
CNS pathogen 
CNS pathogen 
Usually subclinical 
Pruritis, self-trauma, skin 
ulcers 
SPF, specific-pathogen free; CNS, central nervous system. 
rone and ACTH were measured to determine the effects 
of RU-486 on the HPA axis. 
MATERIALS AND METHODS 
Animak. Thirty-seven obese (falfa) and thirty-nine lean 
(Fal?) male and female Zucker rats from standardized litters 
of 8-10 pups/dam were used for this study, starting at 5 wk of 
age. The colony supplying the animals was derived and 
maintained under SPF conditions (41). This colony is part of 
the Animal Models Core, a National Institutes of Health 
(NIH)-funded Clinical Nutrition Research Unit. The founder 
animals were cesarean derived. The colony is housed with 
microisolator filters covering all cages. Air entering the rooms 
is hepa filtered with positive pressure ventilation between the 
animal rooms and the corridors. All materials entering the 
animal rooms are autoclaved. Sentinel rats are routinely 
screened in a laboratory animal health surveillance program, 
and the colony is known to be free of the pathogens listed in 
Table 1 (23, 32). Rats were individually housed in hanging 
wire cages and were provided a stock diet (Ralston Purina) 
and deionized water ad libitum. The animals were main- 
tained on a 12:12-h light-dark cycle (lights on at 6:00 A.M.) at 
24-26°C. The experimental protocols were approved by the 
Institutional Animal Use and Care Committee of the Univer- 
sity of California Davis and were conducted in accordance 
with the NIH “Guide for the Use and Care of Laboratory 
Animals .” 
Assays and data anaZysis. Blood samples for glucose and 
insulin, glucagon, pancreatic polypeptide (PP), corticoste- 
rone, and ACTH determination were placed in tubes contain- 
ing EDTA and 50 ul aprotinin (24 trypsin inhibitory units/ml) 
per milliliter whole blood. All samples were kept on ice until 
centrifugation (2,500 revolutions/min for 20 min at 4°C). The 
plasma was frozen at -20°C until assayed. 
Plasma glucose was assayed by the glucose oxidase method 
with a glucose analyzer (Beckman Instruments, Fullerton, 
CA). Plasma insulin, glucagon, and PP were measured in the 
Radioimmunoassay Core Laboratory of the Diabetes Re- 
search and Training Center at Washington University School 
of Medicine, St. Louis, MO. Plasma insulin was measured 
with a radioimmunoassay using a specific rat insulin anti- 
body and rat insulin standards (Linco Research, St. Louis, 
MO). Plasma immunoreactive glucagon was measured by 
radioimmunoassay with an antibody that has a high degree of 
specificity for the COOH-terminal portion of the glucagon 
molecule (Linco Research). Plasma immunoreactive PP was 
measured in unextracted plasma with a sensitive and specific 
radioimmunoassay for rat PP using a guinea pig-derived 
antisera as previously described (1). Plasma corticosterone 
(46) and ACTH (35) were measured by radioimmunoassay. 
The data in Tables 2-5 and Figs. l-3 are expressed as 
means ? SE. The data were first examined for overall effects 
of genotype, sex, or treatment with a three-factor analysis of 
variance (ANOVA). Comparisons between specific groups 
were made by one-way ANOVA with a Fishers protected 
least-significant difference posttest. 
RESULTS 
Food intake and body weight. Initial food intake 
measurements revealed that both male and female 
obese rats were hyperphagic at 5 wk of age (P < 
0.0001). There were significant overall effects of geno- 
type and sex on food intake measured from day 7 to day 
14 of the experiment. Obese animals were hyperphagic 
relative to lean animals (P < O.OOOl), and male rats ate 
more than female rats (P < 0.0001). There was no 
overall effect of treatment, and RU-486 did not affect 
food intake when RU-486-treated rats were compared 
with the corresponding vehicle-treated obese or lean 
male or female Zucker rats (Table 2). Initial and final 
body weights were greater both in obese female than 
Table 2. FI in Zucker rats before and during 14-day 
administration of RU-486 or vehicle 
Experimental protocok Food intake and body weight were 
measured for 2-4 days prior to RU-486 or vehicle administra- 
tion to obtain baseline values. RU-486 (mifepristone, Roussel 
UCLAF) (30 mg* kg-l *day-l) or vehicle was administered 
subcutaneously for 14 days as reported by Langley and York 
(25). To ensure rapid initial uptake of the drug, the vehicle 
was 70% ethanol (1 ml/kg) and the RU-486 was administered 
in divided doses (15 mg/kg) twice daily for the first 2 days (25). 
Thereafter, RU-486 (30 mg/kg) was administered in peanut 
oil (2 ml/kg) once daily (25). Body weight and food intake were 
measured daily. After 2 wk of treatment, the animals were 
brought to a separate room and killed by decapitation within 
1 min. Trunk blood was collected in EDTA tubes immediately 
after decapitation. Adrenal glands, thymus glands, inguinal 
and gonadal fat depots, interscapular brown adipose tissue 
Baseline Mean Daily FI Total FI 
Treatment n FI, g/day (Days 7-14), g/day (Days 7-14), g 
Female rats 
Lean vehicle 10 12.12 0.3 15.0 + 0.5 104.8 + 3.2 
Lean RU-486 11 13.5 + 0.7 15.0 + 0.3 105.12 2.2 
Obese vehicle 9 20.5 + l.O* 25.2 t 0.7* 176.4 t 4.6* 
Obese RU-486 9 20.5 + 1.2* 25.12 0.7* 176.0 ? 4.6* 
Male rats 
Lean vehicle 8 15.2kO.6 19.8? 0.7 138.6 + 5.1 
Lean RU-486 13 15.7 + 0.3 19.7 + 0.4 131.4 t 3.7 
Obese vehicle 7 21.6 + l.l* 27.12 1.5* 189.4 + 10.6* 
Obese RU-486 9 21.7 t l.l* 26.3 2 0.9* 184.2 t 6.3* 
Values are means t SE; n = no. of animals. FI, feed intake. *P < 
0.01 vs. lean. 
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lean female and obese male than lean male rats (both O.OOOl), and female rats had larger adrenals than male 
P < 0.0001). Th ere were overall effects of genotype and rats (P < 0.0001). RU-486 significantly increased adre- 
sex on body weight gain over the course of the experi- nal weight overall (P < 0.02) and specifically increased 
ment, with obese rats gaining more weight than lean adrenal weight in lean female rats (P < 0.05). Males 
rats (P < 0.0001) and male rats gaining more weight had larger thymus glands than female rats (P < 
than female rats (P < 0.0001). There was no overall 0.0001). Overall, RU-486 treatment decreased thymus 
effect of RU-486 on body weight gain (P = 0.5707). weight (P < 0.0001) and specifically decreased thymus 
RU-486 treatment had no significant overall effect on weight in obese females (P < 0.005), obese males (P < 
body weight gain or any effect when obese and lean O.Ol), and lean males (P < 0.005 vs. vehicle). RU-486 
male or female rats were compared with their corre- administration did not significantly affect ovarian 
sponding vehicle-treated controls. (Fig. 1, A and B). weight in lean or obese female rats (Table 4). 
White adipose tissue and BAT weights. Inguinal and Plasma glucose and pancreatic hormone concentra- 
gonadal fat depot weight and total white adipose tissue tions. Overall, obese animals had higher plasma glu- 
(WAT; inguinal + gonadal weights) were significantly case concentrations than lean animals (P < O.OOOl), 
larger in obese vs. lean rats (both P < 0.0001). Inguinal and male rats had higher plasma glucose concentra- 
fat depot weight was modestly reduced by RU-486 tions than female rats (P < 0.0001). RU-486 signifi- 
treatment in obese female (P < 0.01) rats but not in cantly increased plasma glucose concentrations overall 
lean male or female or obese male rats. There was no (P < 0.002) a n d specifically increased glucose concentra- 
significant effect of RU-486 on gonadal fat depot weight tions in obese male (P < 0.05) and obese female rats 
or on total WAT in any group. BAT weight was larger in (P < 0.05) but no in lean male or female rats (Table 5). t 
both obese males and females than in lean rats (P < Obese rats were hyperinsulinemic relative to lean 
0.0001). RU-486 treatment was without effect on BAT animals (P < O.OOOl), and male animals had higher 
weight (Table 3). plasma insulin concentrations than females (P < 
Adrenal, thymus, and ovary weights. Obese animals 0.0001). RU-486 significantly increased plasma insulin 
had larger adrenal glands than lean animals (P < in obese male rats (P < 0.028). Obese rats had elevated 
plasma glucagon concentrations relative to lean ani- 
A 
300 
0 OBESE RlJ486 (n-9) 
--+-- OBESE VEHICLE (n-9) tions (Table 5). 
mals (P < 0.0001). Male rats had lower plasma PP 
concentrations than females (P < 0.001). RU-486 treat- 
ment did not affect plasma glucagon or PP concentra- 
250 
- LEAN RlJ-466 (wll) 
Plasma corticosterone and ACTH concentrations. 
s 
5 
q --- LEAN VEHICLE (n=lO) 
Plasma corticosterone concentrations were higher in 
200 obese Zucker rats relative to their lean littermates (P < 
8 0.0025). Plasma corticosterone concentrations were 
s 
* 150 
higher in female than in male animals (P < 0.025). 
1 
RU-486 administration suppressed the elevated plasma 
corticosterone concentrations in both obese male and 
100 obese female rats to the concentrations in lean animals 
(both P < 0.02 vs. vehicle) (Fig. 2, A and B). Overall, 
50 Plasma ACTH concentrations were elevated in obese 
0 5 10 15 20 vs. lean rats (P < 0.05). PlasmaACTH was significantly 
DAYS elevated in obese female (P < 0.05) and tended to be 
B - OBESE RlJ46 (n-9) 
elevated in obese male (P < 0.1) rats relative to their 
300 
1 
lean littermates (Fig. 3, A and B). RU-486 administra- 
--a-- OBESE MHICLE (w7) 
1 tion suppressed the elevated plasma ACTH concentra- 
- LEAN RU46 (n=13) 
250 
tions in obese male and female rats (both P < 0.02 vs. 
LEAN VEHICLE (n-9) 
s 
vehicle). RU-486 had no effect on plasma corticosterone 
+ or ACTH in lean animals (Figs. 2,A and B, and 3,A and 
5 
200 B). Antiglucocorticoid and glucocorticoid agonist effects 
Y 
of RU-486 observed in the experiment and the signifi- 
& 
150 cance levels of the effects are compared in Table 6. 
8 DISCUSSION 
loof- r I 
RU-486 
DAYS 
Fig. 1. Body weight before and during a 2-wk period of daily 
subcutaneous injections of RU-486 (30 mgekg-l-day-l) or vehicle in 
female (A) and male (B) lean (bottom plots) and obese (top plots) 
specific-pathogen-free (SPF) Zucker rats; n, no. of rats in each group. 
In a previous study (25), Langley and York reported 
that RU-486 decreased body weight gain in obese but 
not lean 5-wk-old female Zucker rats. We have previ- 
ously reported that administration of RU-486 pre- 
vented body weight gain in lean, but not obese, 12-wk- 
old male Zucker rats and did not affect food intake in 
either the obese or lean animals (18). The present study 
was conducted to examine and clarify the effects of 
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Table 3. Weight of WAT depots and interscapular BAT in SPF Zucker rats after 2-wk administration 
of RU-486 or vehicle 
R713 
Treatment n Inguinal WAT Gonadal WAT Total WAT BAT 
Lean vehicle 
Lean RU-486 
Obese vehicle 
Obese RU-486 
10 
11 
9 
9 
Lean vehicle 8 1.0920.15 1.26kO.15 2.25kO.28 0.43zo.31 
Lean RU-486 13 0.8820.05 0.96t0.06 1.8420.09 0.4120.26 
Obese vehicle 7 6.40+0.42* 4.01~0.30* 10.41+0.68* 1.07 2 ox* 
Obese RU-486 9 5.78+0.42* 3.87+0.30* 9.65+0.55* 0.95+0.55* 
Female rats 
0.65kO.05 0.53 LO.03 1.14+0.10 0.33kO.03 
0.6OkO.02 0.39kO.03 0.9920.04 0.35 20.02 
5.80+0.31* 4.55+0.31* 10.35+0.56* 1.02+0.09* 
4.805 0.41v 4.38+0.33* 9.18+0.87* 0.98*0.07* 
Male rats 
Values are means + SE. WAT, white adipose tissue; BAT, brown adipose tissue. *p < 0.0001 vs. lean; -FP < 0.01 vs. vehicle. 
RU-486 on body weight gain and food intake in obese 
and lean male and female 5-wk-old SPF Zucker rats 
that are documented to be free of a large number of 
pathogenic agents. Because our previous results in the 
older, male animals contrasted with those of Langley 
and York in 5wk-old female Zucker rats, we also 
examined physiological indexes of glucocorticoid activ- 
ity (plasma glucose, thymus and adrenal weight) and 
measured plasma corticosterone and ACTH levels to 
assess the effects of RU-486 on the HPA axis. We found 
no appreciable effect of RU-486 on food intake or body 
weight gain overall or in any of the groups of animals. 
RU-486 has also been reported to be similarly ineffec- 
tive in reducing body weight gain in genetically obese 
(oblob) mice (11). In other experiments in non-SPF 
animals, RU-486 reduced body weight gain without 
reducing food intake in 12-wk-old male Sprague- 
Dawley rats (44), similar to our previous findings in 
12-wk-old lean male Zucker rats (18), whereas, in 
obesity-susceptible Osborne-Mendel rats fed a high-fat 
diet, RU-486 reduced both food intake and body weight 
gain (31). In another species, Siberian hamsters, RU- 
486 had a small effect on body weight but no effect on 
food intake (4). Thus the effects of RU-486 on body 
weight, if observed, can either parallel or occur indepen- 
dently of decreased food intake. The effects observed 
Table 4. Adrenal, thymus, and ovary weights 
in SPF Zucker rats after 2-wk administration 
of RU-486 or vehicle 
Adrenal Thymus Ovary 
Treatment n Wt, mg Wt, mg Wt, mg 
FemaZe rats 
Lean vehicle 10 34.2 t 1.8 296.527.5 83.654.2 
Lean RU-486 11 40.22 1.9* 244.5212.3 100.2+5.9 
Obese vehicle 9 42.251.7-f 381.7226.4 85.726.4 
Obese RU-486 9 47.823.7 263.7t10.7* 84.328.6 
Male rats 
Lean vehicle 8 27.121.1 494.3243.4 
Lean RU-486 13 26.621.3 351.3231.6* 
Obese vehicle 7 36.3+2.3-i- 426.1535.9 
Obese RU-486 9 40.322.2Jf 348.2+29.5* 
Values are means + SE. *P < 0.05 vs. vehicle; TP < 0.05 vs. lean. 
appear to be highly dependent on the animal model 
tested. 
If RU-486 had significant antiglucocorticoid effects in 
the present study, we would have expected increased 
adrenal size as a consequence of reduced feedback 
inhibition by endogenous glucocorticoids on hypotha- 
lamic CRH and pituitary ACTH, leading to increased 
trophic actions ofACTH on the adrenal cortex. Adrenal 
weight was modestly but significantly increased overall 
and in lean female animals by RU-486 administration. 
Because glucocorticoids have potent thymolytic actions 
and adrenalectomy results in thymic hypertrophy, anti- 
glucocorticoid treatment would be expected to result in 
increased thymic weight. However, we found that RU- 
486 reduced thymus weight in SPF Zucker rats, suggest- 
ing a glucocorticoid agonist action of the drug on the 
thymus. Because RU-486 decreased inguinal fat depot 
weight but decreased thymus weight in obese female 
rats, RU-486 may have both glucocorticoid agonist and 
antagonist actions within the same animals. RU-486 
did not exhibit significant antiprogesterone activity in 
female rats as reflected by increased ovarian weight. 
Increased ovarian weight after RU-486 has been ob- 
served in another strain of rats (29); however, these 
animals were considerably older than those in the 
Table 5. Plasma concentrations of glucose 
and pancreatic hormones in SPF Zucker rats 
after 2-wk administration of RU-486 or vehicle 
[Glucose], [Insulin], [ Glucagon] , PPI , 
Treatment n mg/dl pU/ml Pial PWl 
Female rats 
Lean vehicle 10 124?1 4024 150+7 5723 
Lean RU-486 11 128+3 4524 150+5 6Ok4 
Obese vehicle 9 127~3 487?79* 223+18* 6223 
Obese RU-486 9 143*2*-j- 533+109* 223+11* 5925 
Male rats 
Lean vehicle 8 129+5 64+9 15728 49+3 
Lean RU-486 13 139+3 6528 16455 5353 
Obese vehicle 7 160+8* 757+110* 226+21* 5055 
Obese RU-486 9 176+10*? 1115-t156*"f 220-110* 48+5 
Values are means 5 SE. Brackets indicate concentration; PP, 
pancreatic polypeptide. *P < 0.05 vs. lean; tP < 0.05 vs. vehicle. 
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n LEAN VEHICLE (n=lO) 
* 
I 
LEAN OBESE 
l p( 0.02 vs Vehicle 
q LEAN RU486 (n=l 1) 
q OBESE VEHICLE (n=9) 
0 OBESE RU-486 (r-d) 
n LEAN VEHICLE (n=8) 
a 1 q LEAN RU-486 (n=l3) 
q OBESE VEHICLE (n=7) 
2 q OBESE RU-486 (n=9) 
0 
QL 
W 
I- 
co 
0 P 5 
01 
0 
0 
0 
LEAN OBESE 
l p <0.02 vs Vehicle 
Fig. 2. Plasma corticosterone levels at the end of a 2-wk period of 
daily subcutaneous injections of RU-486 (30 mgekg-l-day-l) or 
vehicle in female (A) and male (B) lean and obese SPF Zucker rats. 
present study, and estrus does not occur in rats before 
6-8 wk of age. 
Plasma glucose was significantly increased overall 
and specifically in obese female and lean and obese 
male rats, suggesting glucocorticoid agonist actions on 
hepatic glucose metabolism or insulin-mediated glu- 
cose uptake in these animals. The HPA axis influences 
autonomic activity and insulin action and therefore 
plasma insulin levels. Zucker obese rats are hyperinsu- 
linemic and insulin resistant (8). RU-486 treatment 
further elevated plasma insulin levels in obese male 
rats, suggesting that glucocorticoid agonist action of 
the drug exacerbated insulin resistance and/or insulin 
hypersecretion in these animals. Central administra- 
tion of CRH is known to influence the activity of the 
autonomic nervous system (7, 40), which in turn can 
affect pancreatic insulin, glucagon, and PP secretion 
(20). Plasma glucagon levels were consistently higher 
in obese vs. lean rats, as has been previously described 
(8, 37), but were unaffected by RU-486 administration 
in any of the groups of animals. Some studies have 
suggested that obese Zucker rats have increased nara- 
sympathetic input to the pancreatic islets (12, 36). 
Plasma PP, an index of parasympathetic neural input 
to the pancreas (17, 19), was not different between 
obese and lean animals and was unaffected by RU-486; 
however, plasma PP levels were lower in male than in 
female rats. The physiological significance of this previ- 
ously unreported gender difference in PP levels in rats 
is unknown at this time. Based on measurements of 
pancreatic hormone levels, RU-486 did not appear to 
affect autonomic nervous system activity in this study. 
Plasma corticosterone was elevated in both obese 
female and male vehicle-treated rats relative to lean 
rats. RU-486 decreased the elevated plasma corticoste- 
rone to levels similar to those in lean animals in both 
female and male obese rats. In one previous study, oral 
administration of RU-486 for 4 days increased plasma 
corticosterone in lean but not obese 22-wk-old male 
Zucker rats (33), suggesting an antiglucocorticoid ac- 
tion on the HPA axis in lean rats, whereas in the same 
study prepro-corticotropin releasing factor mRNA lev- 
els in the paraventricular nucleus of the obese rats 
were reduced by RU-486, a glucocorticoid agonist ac- 
A 
120 
100 
= E 80 
2 
- 60 
P 
o 2s 40 
20 
1201 
LEAN OBESE 
* p4 0.02 vs Vehicle 
p 80 
B 
- 60 
F 
y 40 
0 
LEAN OBESE 
m  LEAN VEHICLE (n=l 0) 
q LEAN RU-486 (n=ll) 
a OBESE VEHICLE (n=9) 
0 OBESE RU486 (n=7) 
. 
n LEAN VEHICLE (n=8) 
•] LEAN RU486 (n=l3) 
/ j j  OBESE VEHICLE (n=7) 
c) OBESE RU186 (n=9) 
l p < 0.02 vs Vehicle 
Fig. 3. Plasma ACTH levels at the end of a 2-wk period of daily 
subcutaneous injections of RU-486 (30 mg*kg-l *day-l) or vehicle in 
female (A> and male (B) lean and obese 5-wk-old SPF Zucker rats. 
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Table 6. Antiglucocorticoid and glucocorticoid agonist effects of RU-486 administration 
observed in the experiment 
P Values 
Group 
Glucocorticoid agonist effect 
Decreased thymus wt 
Increased plasma glucose 
Increased plasma insulin 
Decreased plasma corticosterone 
Decreased ACTH 
Antiglucocorticoid effect 
Increased adrenal wt 
Decreased inguinal fat wt 
Decreased total fat wt 
Antiprogesterone effect 
Increased wt ovary 
Not affected by RU-486 
Food intake 
Body wt gain 
Gonadal fat wt 
Brown fat wt 
Plasma glucagon 
Plasma PP 
Overall Lean females Obese females 
0.0001* 0.1501 0.0032* 
0.0018* 0.5163 0.0307* 
0.0571 0.9820 0.6722 
0.0113* 0.5912 0.0182* 
0.0053* 0.4683 0.0194* 
0.0138* 0.0360* 0.0699 
0.0097* 0.8892 0.0072* 
0.0377* 0.7461 0.0679 
0.2456 0.0617 0.8829 
0.3575 0.9517 0.9653 
0.1643 0.0741 0.6290 
0.2100 0.6107 0.5725 
0.3555 0.7496 0.5589 
0.7878 0.5078 0.9999 
0.8176 0.5633 0.6420 
Lean males Obese males 
0.0008* 0.0631* 
0.1519 0.0396* 
0.9594 0.0028* 
0.7101 0.0108* 
0.9871 0.0200* 
0.8599 0.2138 
0.5345 0.1123 
0.4670 0.2328 
0.2388 0.5078 
0.4637 0.4122 
0.3030 0.6584 
0.9521 0.1674 
0.7624 0.7287 
0.4102 0.7072 
All P values by analysis of variance. Order of sensitivity to glucocorticoid agonist actions of RU-486: obese males > obese females > lean 
males > lean females. *Values are significant (P < 0.05). 
tion. RU-486 has been reported to reduce plasma 
corticosterone levels in another animal model of obe- 
sity, the oblob mouse (11). 
Similar to the corticosterone levels, plasma ACTH 
levels in the present study were increased in both 
female and male vehicle-treated obese animals. RU- 
486 administration significantly decreased plasma 
ACTH in both female and male obese rats but had no 
effect in lean animals in the absence of increased HPA 
activity. The suppressive effect of RU-486 on the HPA 
axis along with the thymolytic actions and effects on 
glucose metabolism strongly suggest that RU-486 acted 
primarily as a glucocorticoid agonist in this study. In 
contrast, Langley and York (25) found that plasma 
corticosterone was substantially increased in animals 
’ that received RU-486 injections. Although plasma ACTH 
levels were not measured in the Langley and York 
study, plasma corticosterone levels in the vehicle- 
treated animals were up to five times higher than in the 
present study and were not elevated in obese vs. lean 
animals as has been reported in other studies (16). This 
is a major difference between the animals used for the 
two studies, which suggests that the SPF Zucker rats 
used in the present study respond differently to RU-486 
than conventionally housed animals of the same age. It 
is possible that in conventionally housed animals the 
activity of the HPA axis is increased, perhaps due to 
chronic stress induced by endemic pathogens (23, 32), 
and that RU-486 can act as a glucocorticoid antagonist 
under these conditions. However, in SPF animals with- 
out elevated HPA activity, RU-486 clearly has a number 
of glucocorticoid agonist actions. Furthermore, in con- 
trast to the SPF animals, the conventionally housed 
animals in the Langley and York study had low initial 
body weights in both lean and obese rats, reduced final 
body weight in vehicle-treated obese animals, and an 
absence of hyperphagia at 5 wk of age (25). Other 
abnormalities included very low plasma glucose levels 
in all animals (62-69 mg/dl) and fourfold higher insulin 
levels in the lean rats than in our lean SPF animals. It 
is therefore likely that the conflicting effects of RU-486 
in the two studies reflect major differences between 
SPF and conventionally maintained animals. Another 
possible explanation for the divergent effects of RU-486 
in the two studies could be differences in the drug itself. 
Although the same batch of RU-486 was used for the 
two studies, differences in the storage conditions could 
have influenced the potency and therefore the relative 
antagonist/agonist actions of the drug. However, this 
cannot be determined in the absence of receptor bind- 
ing studies and dose-response curves. 
RU-486 has been shown to have both glucocorticoid 
antagonistic and agonist actions in experimental trials 
in human subjects (3, 24, 26) and in nonhuman pri- 
mates (21, 27). Although potent glucocorticoid antago- 
nist actions for RU-486 have been reported both in vivo 
and in vitro (3, 9, 14, ZS), many of these experiments 
have examined the ability of RU-486 to antagonize the 
effects of glucocorticoid agonists such as dexametha- 
sone on glucocorticoid-mediated events but did not 
evaluate the action of RU-486 in the presence of basal 
levels of endogenous glucocorticoid hormones. In adre- 
nalectomized rats with or without low-dose corticoste- 
rone replacement, RU-486 had glucocorticoid receptor 
agonist actions to decrease thymus weight and inhibit 
plasma ACTH concentrations (5). In another study 
examining dexamethasone-induced hypertension in 
rats, RU-486 effectively blocked the hypertensive ef- 
fects of concurrent dexamethasone administration, but 
RU-486 alone actually caused small but significant 
increases of blood pressure (22). Thus, when ambient 
glucocorticoid levels are low, RU-486 can display signifi- 
cant glucocorticoid agonist effects (42). Several studies 
have implicated activation of a protein kinase A (PKA) 
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adenosine 3’,5’-cyclic monophosphate-dependent path- 7. 
way in the agonist actions of RU-486 (15, 30). These 
studies suggest that the phosphorylation of a coactiva- 
tor by PKApotentiates the response to agonists and can 8 
’ also cause transcriptional activation by type II antago- 
nists, resulting in agonist actions by antagonists (29, 
30). The agonist effects of RU-486 observed in several 
tissues in the present study could be dependent on the 
9 
l 
activation state of the PKA signal transduction path- 
way in those tissues. 
Brown, M. R., L. A. Fisher, J. Spiess, C. Rivier, J. Rivier, 
and W. Vale. Corticotropin-releasing factor: actions on the 
sympathetic nervous system and metabolism. Endocrinology 
111: 928-931,1982. 
Bryce, G. F., P. R. Johnson, A. C. Sullivan, and J. S. Stern. 
Insulin and glucagon: plasma levels and pancreatic release in the 
genetically obese Zucker rat. Horm. Metab. Res. 9: 366-370, 
1977. 
In summary, RU-486 does not affect food intake or 10. 
body weight gain in 5-wk-old SPF Zucker rats. In 
addition, RU-486 has primarily glucocorticoid agonist 
activity in SPF Zucker rats of this age. The conflicting 11. 
effects of RU-486 found in the present study with those 
found in a previous study may reflect marked differ- 
ences in the activity of the HPA axis between convention- 
ally maintained and SPF animals. Therefore, the net 
12 
’ 
effect of this mixed agonist/antagonist on glucocorticoid- 
sensitive tissues is highly dependent on the physiologi- 
cal state of the test subjects. Caution should be exer- l3 
cised in interpreting the results from experiments 
utilizing this compound, and independent physiological 
measurements of glucocorticoid agonist and antigluco- 14. 
corticoid actions should be monitored along with in- 
dexes of HPA activity. 
15. 
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